Design of an Osteonecrosis Experimental Model in Rats. Histomorphometric Study

Fil: Fontana, Sebastían. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Fisiología; Argentina.Fil: Hernández, Mabel Abigail. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía B; Argentina.Fil: Rocamundi, Marina. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía Patológica A; Argentina.Fil: Vázquez Mosquera, Ana Paula. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Instituto de Investigaciones en Ciencias de la Salud. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Medication-related osteonecrosis of the jaw (MRONJ) is a non-resolving lesion developing in the maxillary bones, that persists for more than 8 weeks. It is common in patients receiving antiresorptive and oncologic medications such as bisphosphonates, denosumab and antiangiogenic drugs. So far, there is no effective treatment for its resolution.www.iadr.orgFil: Fontana, Sebastían. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Fisiología; Argentina.Fil: Hernández, Mabel Abigail. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía B; Argentina.Fil: Rocamundi, Marina. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía Patológica A; Argentina.Fil: Vázquez Mosquera, Ana Paula. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Instituto de Investigaciones en Ciencias de la Salud. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Otras Ciencias de la Salu

Effects of melatonin on a drug-associated model of maxillary osteonecrosis

Fil: Hernández, Mabel Abigail. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía B; Argentina.Fil: Vázquez Mosquera, Ana Paula. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Fontana, Sebastían. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Fisiología; Argentina.Fil: Carpentieri, Ágata Rita. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Instituto de Investigaciones en Ciencias de la Salud. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.El propósito de este trabajo es estudiar los efectos de la melatonina (MEL) como opción terapéutica en el modelo de ONMAM.The aim of this presentation is to study the effects of melatonin (MEL) as a therapeutic option in the MRONJ modelww.saio.org.arFil: Hernández, Mabel Abigail. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Anatomía B; Argentina.Fil: Vázquez Mosquera, Ana Paula. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Fontana, Sebastían. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Fisiología; Argentina.Fil: Carpentieri, Ágata Rita. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Carpentieri, Ágata Rita. Instituto de Investigaciones en Ciencias de la Salud. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina.Otras Ciencias de la Salu

Estudiantes voluntarios: mediadores entre la universidad y la sociedad

La extensión toma como principio rector la función social de la universidad, orientada a la proyección de la cultura universitaria hacia la sociedad y a la atención de sus problemas. Es la función extensionista la que habilita el diálogo de la universidad con los distintos actores sociales, productivos, culturales y gubernamentales y el intercambio de saberes, en los que el saber científico-humanístico y saber popular-social comparten una misma jerarquía. Es la extensión un eje fundamental en la formación de los profesionales y ha sido revalorizada mediante el Programa del Voluntariado Universitario, que abre la posibilidad que alumnos universitarios se inserten y se relacionen con diferentes sectores de la sociedad. El objetivo de este trabajo fue fomentar el compromiso social y la participación activa de los estudiantes universitarios en la identificación de problemáticas de salud comunitaria y la adquisición de hábitos saludables a través de un trabajo en red de la escuela con otras instituciones.En esta línea, desde el año 2013, se vienen desarrollando proyectos que reúnen en un trabajo interdisciplinario, a la comunidad educativa de la escuela Curaca Lino Acevedo de Córdoba y un equipo conformado por docentes y estudiantes voluntarios de distintas Facultades de la UNC; considerando a la escuela como una de las instituciones privilegiadas para el desarrollo de la ciudadanía, de la conciencia comunitaria sobre la salud, y capaz de empoderar a las personas para hacer frente a situaciones de vulnerabilidad, privación o falta de derechos. En este contexto, el voluntario se convierte en un mediador entre dos realidades, la universitaria y la comunitaria, y como tal, se acerca, se inserta y empatiza con la comunidad, captando sus necesidades, carencias y fortalezas. Es así como a partir de un diagnóstico identifica prácticas que no favorecen el cuidado de la salud y reflexiona sobre creencias populares y hábitos para impulsar las modificaciones del comportamiento, que requieran ser revisados. El estudiante voluntario se va acercando e incorporando a la comunidad educativa desde un trabajo colaborativo e interdisciplinario. En este sentido, profesionales-docentes y alumnos de las ciencias de la salud (Facultad de Odontología, Ciencias Medica y Nutrición), de las ciencias agropecuarias y las ciencias de la educación, aportan sus distintas miradas y enfoques en la elaboración y ejecución de estrategias de intervención. La participación de los estudiantes en estos equipos interdisciplinarios es también ocasión tanto para el desarrollo de la competencia comunicativa social y ciudadana, como para vivenciar valores de respeto, tolerancia, compromiso y solidaridad, indispensables para desempeñarse en la sociedad actual.Fil: Barembaum, Silvina Ruth. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Introducción a la Física y Química Biológica B; Argentina.Fil: Rezzónico, María Silvina. Universidad Nacional de Córdoba. Facultad de Odontología. Asesoría Pedagógica; Argentina.Fil: Scatena, María Gabriela. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra Química Biológica B; Argentina.Fil: Giraudo, Matías. Universidad Nacional de Córdoba. Facultad de Odontología. Cátedra de Diagnóstico por Imágenes A; Argentina.Otras Ciencias de la Salu

The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation

Rapid Molecular Diagnosis of Genetically Inherited Neuromuscular Disorders Using Next-Generation Sequencing Technologies

Neuromuscular diseases are genetically highly heterogeneous, and differential diagnosis can be challenging. Over a 3-year period, we prospectively analyzed 268 pediatric and adult patients with a suspected diagnosis of inherited neuromuscular disorder (INMD) using comprehensive gene-panel analysis and next-generation sequencing. The rate of diagnosis increased exponentially with the addition of genes to successive versions of the INMD panel, from 31% for the first iteration (278 genes) to 40% for the last (324 genes). The global mean diagnostic rate was 36% (97/268 patients), with a diagnostic turnaround time of 4–6 weeks. Most diagnoses corresponded to muscular dystrophies/myopathies (68.37%) and peripheral nerve diseases (22.45%). The most common causative genes, TTN, RYR1, and ANO5, accounted for almost 30% of the diagnosed cases. Finally, we evaluated the utility of the differential diagnosis tool Phenomizer, which established a correlation between the phenotype and molecular findings in 21% of the diagnosed patients. In summary, comprehensive gene-panel analysis of all genes implicated in neuromuscular diseases facilitates a rapid diagnosis and provides a high diagnostic yield

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Background: Additional safe and efficacious vaccines are needed to control the COVID-19 pandemic. We aimed to analyse the efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate. Methods: HERALD is a randomised, observer-blinded, placebo-controlled, phase 2b/3 clinical trial conducted in 47 centres in ten countries in Europe and Latin America. By use of an interactive web response system and stratification by country and age group (18–60 years and ≥61 years), adults with no history of virologically confirmed COVID-19 were randomly assigned (1:1) to receive intramuscularly either two 0·6 mL doses of CVnCoV containing 12 μg of mRNA or two 0·6 mL doses of 0·9% NaCl (placebo) on days 1 and 29. The primary efficacy endpoint was the occurrence of a first episode of virologically confirmed symptomatic COVID-19 of any severity and caused by any strain from 15 days after the second dose. For the primary endpoint, the trial was considered successful if the lower limit of the CI was greater than 30%. Key secondary endpoints were the occurrence of a first episode of virologically confirmed moderate-to-severe COVID-19, severe COVID-19, and COVID-19 of any severity by age group. Primary safety outcomes were solicited local and systemic adverse events within 7 days after each dose and unsolicited adverse events within 28 days after each dose in phase 2b participants, and serious adverse events and adverse events of special interest up to 1 year after the second dose in phase 2b and phase 3 participants. Here, we report data up to June 18, 2021. The study is registered at ClinicalTrials.gov, NCT04652102, and EudraCT, 2020–003998–22, and is ongoing. Findings: Between Dec 11, 2020, and April 12, 2021, 39 680 participants were enrolled and randomly assigned to receive either CVnCoV (n=19 846) or placebo (n=19 834), of whom 19 783 received at least one dose of CVnCoV and 19 746 received at least one dose of placebo. After a mean observation period of 48·2 days (SE 0·2), 83 cases of COVID-19 occurred in the CVnCoV group (n=12 851) in 1735·29 person-years and 145 cases occurred in the placebo group (n=12 211) in 1569·87 person-years, resulting in an overall vaccine efficacy against symptomatic COVID-19 of 48·2% (95·826% CI 31·0–61·4; p=0·016). Vaccine efficacy against moderate-to-severe COVID-19 was 70·7% (95% CI 42·5–86·1; CVnCoV 12 cases in 1735·29 person-years, placebo 37 cases in 1569·87 person-years). In participants aged 18–60 years, vaccine efficacy against symptomatic disease was 52·5% (95% CI 36·2–64·8; CVnCoV 71 cases in 1591·47 person-years, placebo, 136 cases in 1449·23 person-years). Too few cases occurred in participants aged 61 years or older (CVnCoV 12, placebo nine) to allow meaningful assessment of vaccine efficacy. Solicited adverse events, which were mostly systemic, were more common in CVnCoV recipients (1933 [96·5%] of 2003) than in placebo recipients (1344 [67·9%] of 1978), with 542 (27·1%) CVnCoV recipients and 61 (3·1%) placebo recipients reporting grade 3 solicited adverse events. The most frequently reported local reaction after any dose in the CVnCoV group was injection-site pain (1678 [83·6%] of 2007), with 22 grade 3 reactions, and the most frequently reported systematic reactions were fatigue (1603 [80·0%] of 2003) and headache (1541 [76·9%] of 2003). 82 (0·4%) of 19 783 CVnCoV recipients reported 100 serious adverse events and 66 (0·3%) of 19 746 placebo recipients reported 76 serious adverse events. Eight serious adverse events in five CVnCoV recipients and two serious adverse events in two placebo recipients were considered vaccination-related. None of the fatal serious adverse events reported (eight in the CVnCoV group and six in the placebo group) were considered to be related to study vaccination. Adverse events of special interest were reported for 38 (0·2%) participants in the CVnCoV group and 31 (0·2%) participants in the placebo group. These events were considered to be related to the trial vaccine for 14 (<0·1%) participants in the CVnCoV group and for five (<0·1%) participants in the placebo group. Interpretation: CVnCoV was efficacious in the prevention of COVID-19 of any severity and had an acceptable safety profile. Taking into account the changing environment, including the emergence of SARS-CoV-2 variants, and timelines for further development, the decision has been made to cease activities on the CVnCoV candidate and to focus efforts on the development of next-generation vaccine candidates. Funding: German Federal Ministry of Education and Research and CureVac